Sudhir Kumar, Alok K. Verma, Richa Rani, Akanksha Sharma, Jiang Wang, Shimul A. Shah, Jaideep Behari, Rosa Salazar Gonzalez, Rohit Kohli, Chandrashekhar R. Gandhi – 7 February 2020
Mohamed A. Abdallah, Ashwani K. Singal – 7 February 2020
Gary P. Jeffrey, Louisa G. Gordon, Michelle M. Hill, Grant A. Ramm – 7 February 2020
Sarah Raevens, Michael B. Fallon – 7 February 2020
Xiao Liu, Sara Brin Rosenthal, Nairika Meshgin, Jacopo Baglieri, Sami G. Musallam, Karin Diggle, Kevin Lam, Raymond Wu, Stephanie Q. Pan, Yibu Chen, Ken Dorko, Sharon Presnell, Chris Benner, Mojgan Hosseini, Hidekazu Tsukamoto, David Brenner, Tatiana Kisseleva – 6 February 2020 – Alcoholic liver disease (ALD) is a leading cause of cirrhosis in the United States, which is characterized by extensive deposition of extracellular matrix proteins and formation of a fibrous scar. Hepatic stellate cells (HSCs) are the major source of collagen type 1 producing myofibroblasts in ALD fibrosis.
Yulan Zhao, Melanie Tran, Li Wang, Dong‐Ju Shin, Jianguo Wu – 5 February 2020 – Liver regeneration requires intrahepatic and extrahepatic metabolic reprogramming to meet the high hepatic bioenergy demand for liver cell repopulation. This study aims to elucidate how pyruvate dehydrogenase kinase 4 (PDK4), a critical regulator of glucose and lipid metabolism, coordinates metabolic regulation with efficient liver growth. We found that hepatic Pdk4 expression was elevated after two‐thirds partial hepatectomy (PHx).
Hye‐Mee Kwon, Gyu‐Sam Hwang – 5 February 2020
Yamini Natarajan, Jennifer R. Kramer, Xian Yu, Liang Li, Aaron P. Thrift, Hashem B. El‐Serag, Fasiha Kanwal – 5 February 2020
Won Ho Kim, Seong‐Mi Yang, Kook Hyun Lee – 5 February 2020
Philip Grant, Fabienne Shumbusho, Jennifer Ilo Van Nuil, Fredrick Kateera, Joia Mukherjee, Jules Kabahizi, Fabien Ntaganda, Sabin Nsanzimana, Aimable Mbituyumuremyi, Makuza Jean Damascene, Claude Mambo Muvunyi, Constance Mukabatsinda, Emmanuel Musabeyezu, Cyprien Ntirenganya, Neil Gupta – 4 February 2020 – Direct‐acting antivirals for hepatitis C virus (HCV) are highly effective and well‐tolerated. However, only a small percentage of HCV‐infected individuals globally have received therapy.